News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Glickman Mark A
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 07/28/2023 |
4
| Glickman Mark A (Director) has filed a Form 4 on NeuroBo Pharmaceuticals, Inc.|
Txns:
| Granted 25,000 shares
@ $0
Granted 12,500 shares
@ $0 |
|
| 12/09/2022 |
4
| Glickman Mark A (Co-CEO) has filed a Form 4 on TherapeuticsMD, Inc.|
Txns:
| Sold 440 shares
@ $4.9215, valued at
$2.2k
Exercised 1,734 restricted stock units
@ $0 |
|
| 03/28/2022 |
4
| Glickman Mark A (Chief Business Officer) has filed a Form 4 on TherapeuticsMD, Inc.|
Txns:
| Granted 260,000 restricted stock units
@ $0 |
|
| 10/15/2021 |
4
| Glickman Mark A (Chief Business Officer) has filed a Form 4 on TherapeuticsMD, Inc.|
Txns:
| Granted 260,000 rights
@ $0
Granted 260,000 restricted stock units
@ $0
Granted 400,000 restricted stock units
@ $0 |
|
| 01/03/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/21/2018 |
4
| Glickman Mark A (Chief Commercial Officer) has filed a Form 4 on Aralez Pharmaceuticals Inc.|
Txns:
| Sold 5,725 shares
@ $1.7, valued at
$9.7k
|
|
| 05/12/2017 |
4
| Glickman Mark A (Chief Commercial Officer) has filed a Form 4 on Aralez Pharmaceuticals Inc. |
| 06/24/2016 |
4
| Glickman Mark A (Chief Commercial Officer) has filed a Form 4 on Aralez Pharmaceuticals Inc.|
Txns:
| Paid exercise price by delivering 10,803 shares
@ $3.34, valued at
$36.1k
|
|
| 05/18/2016 |
4
| Glickman Mark A (Chief Commercial Officer) has filed a Form 4 on Aralez Pharmaceuticals Inc.|
Txns:
| Bought 25,000 shares
@ $3.682, valued at
$92.1k
|
|
| 03/18/2016 |
4
| Glickman Mark A (Chief Commercial officer) has filed a Form 4 on Aralez Pharmaceuticals Inc.|
Txns:
| Granted 45,553 shares
@ $0
Granted 38,559 options to buy
@ $3.8, valued at
$146.5k
|
|
| 02/17/2016 |
4
| Glickman Mark A (Chief Commercial Officer) has filed a Form 4 on Aralez Pharmaceuticals Inc.|
Txns:
| Granted 86,863 shares
@ $0 |
|
| 02/09/2016 |
4
| Glickman Mark A (Chief Commercial Officer) has filed a Form 4 on Aralez Pharmaceuticals Inc.|
Txns:
| Acquired 29,137 shares
@ $0 |
|
| 06/24/2015 |
4
| Glickman Mark A (Chief Commercial Officer) has filed a Form 4 on POZEN INC /NC|
Txns:
| Granted 29,137 shares
@ $0 |
|
| 01/30/2015 |
4
| Glickman Mark A (EVP - Sales and Marketing) has filed a Form 4 on AUXILIUM PHARMACEUTICALS INC|
Txns:
| Disposed of 27,911 shares
@ $36.53, valued at
$1M
Disposed of 27,500 options to buy
@ $20.07, valued at
$551.9k
Disposed of 5,000 options to buy
@ $26.87, valued at
$134.4k
Disposed of 24,750 options to buy
@ $18.3, valued at
$452.9k
Disposed of 31,200 options to buy
@ $28.3, valued at
$883k
|
|
| 11/24/2014 |
4
| Glickman Mark A (EVP - Sales and Marketing) has filed a Form 4 on AUXILIUM PHARMACEUTICALS INC|
Txns:
| Sold 7,202 shares
@ $33.1801, valued at
$239k
Sold 40,750 shares
@ $33.1625, valued at
$1.4M
Exercised 27,500 options to buy
@ $20.07, valued at
$551.9k
Exercised 5,000 options to buy
@ $26.87, valued at
$134.4k
Exercised 8,250 options to buy
@ $18.3, valued at
$151k
|
|
| 02/20/2014 |
4
| Glickman Mark A (EVP - Sales and Marketing) has filed a Form 4 on AUXILIUM PHARMACEUTICALS INC|
Txns:
| Granted 6,375 shares
@ $0
Paid exercise price by delivering 704 shares
@ $28.3, valued at
$19.9k
Granted 12,500 shares
@ $0
Granted 31,200 options to buy
@ $28.3, valued at
$883k
Granted 24,000 options to buy
@ $0 |
|
| 02/11/2014 |
4
| Glickman Mark A (EVP - Sales and Marketing) has filed a Form 4 on AUXILIUM PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 1,986 shares
@ $23.68, valued at
$47k
|
|
| 02/04/2014 |
4
| Glickman Mark A (EVP - Sales and Marketing) has filed a Form 4 on AUXILIUM PHARMACEUTICALS INC|
Txns:
| Paid exercise price by delivering 388 shares
@ $24.7, valued at
$9.6k
|
|
| 02/11/2013 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 07/20/2012 |
4
| Glickman Mark A (EVP - Sales and Marketing) has filed a Form 4 on AUXILIUM PHARMACEUTICALS INC|
Txns:
| Granted 10,000 options to buy
@ $26.87, valued at
$268.7k
|
|
|
|